Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia

E-ISSN： 1365-2141|170|5|734-736

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.170, Iss.5, 2015-09, pp. : 734-736

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma

Case Reports in Oncology, Vol. 10, Iss. 1, 2017-01 ,pp. : 127-129

Karger

Access to resources Recommend Favorite

Rituximab in the treatment of autoimmune haemolytic anaemia

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 79, Iss. 5, 2015-05 ,pp. : 709-719

John Wiley & Sons Inc

Access to resources Recommend Favorite

Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 1, 2015-07 ,pp. : 125-128

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 4, 2015-08 ,pp. : 445-456

John Wiley & Sons Inc

Access to resources Recommend Favorite

Eryptosis in autoimmune haemolytic anaemia

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 100, Iss. 1, 2018-01 ,pp. : 36-44

John Wiley & Sons Inc

Access to resources Recommend Favorite